Literature DB >> 24613188

Effects of sildenafil on prognosis in patients with pulmonary hypertension after left-sided valvular surgery.

Gengxi Jiang, Bailing Li, Guanxin Zhang, Enhong Xu, Yang Liu, Zhiyun Xu.   

Abstract

INTRODUCTION: Sildenafil (Viagra, Pfizer) is being used to treat pulmonary hypertension (PH). However, there are limited data on the effects of sildenafil on patients with PH after left-sided valvular surgery. The purpose of this study was to determine the optimal dosage and the effects of sildenafil on prognosis of patients with PH after left-sided valvular surgery.
METHODS: This randomised controlled trial, double-blind study enrolled patients with PH undergoing left-sided valvular surgery in our hospital from January to December, 2010. Ninety patients were enrolled. And 0.5 mg/kg sildenafil citrate or placebo was administered through nasogastric tubes, the haemodynamics changes in the 0.5/1/2/4 hours were assessed. The sildenafil citrate/placebo was continued to the discharges and the early prognoses of these patients were compared.
RESULTS: Compared with placebo, a 0.5 mg/kg dose of sildenafil significantly reduced the time of mechanical ventilation, stay-in-ICU and hospitalisation duration.
CONCLUSIONS: Sildenafil might be beneficial to the early prognosis of patients with PH after left-sided valvular surgery.
Copyright © 2014 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Haemodynamic; Postoperative period; Pulmonary artery hypertension; Sildenafil citrate; Valvular heart disease

Mesh:

Substances:

Year:  2014        PMID: 24613188     DOI: 10.1016/j.hlc.2013.12.014

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  5 in total

Review 1.  Postoperative Right Ventricular Failure in Cardiac Surgery.

Authors:  Victor H Nieto Estrada; Daniel L Molano Franco; Albert A Valencia Moreno; Jose A Rojas Gambasica; Cristian C Cortes Nunez
Journal:  Cardiol Res       Date:  2016-12-31

2.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.

Authors:  Javier Bermejo; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subías; José Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Eduardo de Teresa; José R González-Juanatey; Arturo Evangelista; Teresa Mombiela; Ana González-Mansilla; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2018-04-14       Impact factor: 29.983

3.  Pre-Operative Sildenafil for Patients With Pulmonary Hypertension Undergoing Mitral Valve Surgery: A Systematic Review and Meta-Analysis.

Authors:  Danielle Louis E Villanueva; Ruth Divine Agustin; Elmer Jasper Llanes
Journal:  Cardiol Res       Date:  2019-11-24

4.  Phosphodiesterase 5 inhibitors for pulmonary hypertension.

Authors:  Hayley Barnes; Zoe Brown; Andrew Burns; Trevor Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-01-31

5.  Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial.

Authors:  Tracy Kumar; Hardeep Aujla; Marcin Woźniak; Will Dott; Nikol Sullo; Lathishia Joel-David; Paolo Pais; Dawn Smallwood; Douglas Miller; Bryony Eagle-Hemming; Ana Suazo Di Paola; Shaun Barber; Cassandra Brookes; Nigel J Brunskill; Gavin J Murphy
Journal:  Br J Anaesth       Date:  2020-04-01       Impact factor: 9.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.